Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
 Disease Category: Breast Cancer
Location: United States, CA

Trial Information

Expression of P16INK4a As a Predictor of Myelosuppression in Patients with Breast Cancer

You have been asked to participate in this research study because you have been diagnosed with breast cancer and are considering a new course of chemotherapy. The purpose of this research study is to measure the association between the expression of a specific protein, p16INK4a (also called p16), and myelosuppression (suppressed or decreased bone marrow activity) due to chemotherapy in patients with breast cancer. Another purpose of this study is to explore whether personal habits (exercise, smoking and alcohol consumption), or health care conditions may be associated with the level of p16 in someone’s blood. Your active participation in the study may last up to 12 months.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.